414.30
前日終値:
$417.20
開ける:
$415.52
24時間の取引高:
2.03M
Relative Volume:
0.77
時価総額:
$223.60B
収益:
$37.30B
当期純損益:
$7.80B
株価収益率:
28.81
EPS:
14.3793
ネットキャッシュフロー:
$8.60B
1週間 パフォーマンス:
+6.23%
1か月 パフォーマンス:
+14.01%
6か月 パフォーマンス:
+13.02%
1年 パフォーマンス:
+45.32%
Amgen Inc Stock (AMGN) Company Profile
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
AMGN
Amgen Inc
|
414.30 | 203.07B | 37.30B | 7.80B | 8.60B | 14.38 |
|
LLY
Lilly Eli Co
|
1,215.02 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
|
JNJ
Johnson Johnson
|
259.80 | 640.91B | 97.93B | 21.04B | 17.80B | 8.6278 |
|
ABBV
Abbvie Inc
|
250.09 | 453.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
|
MRK
Merck Co Inc
|
130.42 | 322.95B | 65.51B | 8.93B | 14.12B | 3.5532 |
|
NVS
Novartis Ag Adr
|
154.61 | 296.72B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-21 | 開始されました | Canaccord Genuity | Hold |
| 2026-03-10 | 開始されました | Jefferies | Hold |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-01-20 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-12-05 | アップグレード | Erste Group | Hold → Buy |
| 2025-11-24 | 再開されました | Truist | Hold |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-09-03 | 再開されました | Raymond James | Mkt Perform |
| 2025-05-20 | 再開されました | Guggenheim | Neutral |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-14 | ダウングレード | Truist | Buy → Hold |
| 2024-09-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | アップグレード | Barclays | Underweight → Equal Weight |
| 2024-05-03 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 再開されました | Raymond James | Mkt Perform |
| 2024-02-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-02 | アップグレード | Truist | Hold → Buy |
| 2023-10-20 | 再開されました | JP Morgan | Neutral |
| 2023-10-17 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 再開されました | BofA Securities | Neutral |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-04-24 | 繰り返されました | Oppenheimer | Outperform |
| 2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 繰り返されました | Truist | Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Underperform |
| 2022-10-31 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2022-10-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-09 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-09 | 繰り返されました | Jefferies | Buy |
| 2022-02-09 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 繰り返されました | Oppenheimer | Outperform |
| 2022-02-09 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Buy |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-09-23 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 開始されました | Daiwa Securities | Buy |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-10-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | アップグレード | Truist | Hold → Buy |
| 2020-10-09 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | ダウングレード | Truist | Buy → Hold |
| 2020-10-08 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 再開されました | Guggenheim | Neutral |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-03-30 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 開始されました | Raymond James | Mkt Perform |
| 2019-12-17 | 再開されました | Morgan Stanley | Overweight |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-11-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-08-19 | ダウングレード | Mizuho | Buy → Neutral |
| 2019-05-23 | アップグレード | Citigroup | Neutral → Buy |
すべてを表示
Amgen Inc (AMGN) 最新ニュース
Amgen (NASDAQ:AMGN) Sets New 12-Month HighTime to Buy? - MarketBeat
Amgen stock jumps as investors appear to look past Tavneos overhang and toward earnings - Quiver Quantitative
Amgen shares may move 4.6% on Aug. 4 earnings release By Investing.com - Investing.com South Africa
Earnings Preview: Amgen (AMGN) Q2 Earnings Expected to Decline - Yahoo Finance
Amgen (AMGN) Expected to Post Earnings on Tuesday - MarketBeat
Amgen stock hits all-time high at 391.3 USD - Investing.com
Amgen makes case to continue selling drug that FDA claims can be deadly - The Business Journals
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees - The Motley Fool
Barclays Adjusts Amgen Price Target to $360 From $350, Maintains Equalweight Rating - marketscreener.com
The Manufacturers Life Insurance Company Raises Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Bought by Quantinno Capital Management LP - MarketBeat
Empowered Funds LLC Sells 38,200 Shares of Amgen Inc. $AMGN - MarketBeat
Former AbbVie, Amgen exec Severino takes the reins at Sarepta - FirstWord Pharma
For Himself and His Daughters: One Father’s Journey with Thyroid Eye Disease (TED) - Amgen
Amgen stock trades steadily as investors weigh recent earnings and pipeline milestones - Ad-hoc-news.de
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo! Finance Canada
Amgen price bolsters gainsForecast today27-07-2026 - Economies.com
Amgen Stock Erased a 17% Drawdown. A MariTide Switch Study Explains Why. - TIKR.com
Orbimed Advisors LLC Purchases Shares of 39,900 Amgen Inc. $AMGN - MarketBeat
Price-Driven Insight from (AMGN) for Rule-Based Strategy - Stock Traders Daily
Amgen stock extends focus on earnings and guidance - Ad-hoc-news.de
Amgen stock trades steadily as revenue growth and obesity pipeline shape investor focus - Ad-hoc-news.de
Amgen stock trades steady as oncology and cardiovascular pipeline supports valuation - Ad-hoc-news.de
Amgen (AMGN) Beat Revenue Forecasts, Is The Stock Overvalued? - simplywall.st
Amgen stock steadies after Q2 2026 growth - AD HOC NEWS
Lombard Odier Asset Management Switzerland SA Has $14.53 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Purchased by OMERS ADMINISTRATION Corp - MarketBeat
Amgen Inc. $AMGN Shares Sold by Healthcare of Ontario Pension Plan Trust Fund - MarketBeat
Entropy Technologies LP Buys Shares of 9,161 Amgen Inc. $AMGN - MarketBeat
Gabelli Funds LLC Reduces Stake in Amgen Inc. $AMGN - MarketBeat
Aristotle Atlantic Partners LLC Purchases Shares of 4,000 Amgen Inc. $AMGN - MarketBeat
Amgen stock trades steadily as oncology and cardiovascular pipeline supports long term growth - AD HOC NEWS
Amgen stock trims losses as Repatha data and oncology pipeline support long term growth - AD HOC NEWS
Why MrBeast, Stand Up To Cancer, and Amgen Joined Forces to Support Pediatric Cancer Research - Amgen
Amgen Inc (AMG) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Amgen stock trades steadily as investors weigh Repatha growth and recent earnings - AD HOC NEWS
Amgen Inc (AMGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aristotle Capital Management LLC Lowers Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen stock edges higher as KRAS lung cancer data and revenue growth support outlook - AD HOC NEWS
Amgen stock trades steadily as recent earnings and obesity drug pipeline shape outlook - AD HOC NEWS
Amgen submits new data to challenge FDA's proposal to withdraw Tavneos - Reuters
Amgen Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Amgen shares new analysis with FDA in bid to keep Tavneos on the market - Endpoints News
Amgen stock trades steady as oncology and cardiovascular drugs support outlook - AD HOC NEWS
Amgen Inc. Revenue Breakdown – HAN:AMG - TradingView
Amgen hands in data package in hopes of FDA hearing for Tavneos defense - Fierce Pharma
Amgen submits new data to challenge FDA’s proposal to withdraw Tavneos - 1470 & 100.3 WMBD
Amgen stock trades steady as recent earnings and pipeline updates shape investor focus - AD HOC NEWS
Amgen Says Strongly Disagrees With FDA'S Proposal To Withdraw Tavneos From The U.S. Market - TradingView
Amgen Inc. $AMGN Shares Sold by Oak Associates Ltd. OH - MarketBeat
Public Employees Retirement System of Ohio Grows Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc (AMGN) 財務データ
収益
当期純利益
現金流量
EPS
Amgen Inc (AMGN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Miller Derek | SVP, Human Resources |
Aug 06 '26 |
Sale |
402.54 |
3,890 |
1,565,898 |
12,462 |
| Grygiel Nancy A. | SVP & CCO |
Aug 06 '26 |
Option Exercise |
177.41 |
2,970 |
526,906 |
9,310 |
| Grygiel Nancy A. | SVP & CCO |
Aug 06 '26 |
Sale |
402.16 |
2,970 |
1,194,415 |
7,340 |
大文字化:
|
ボリューム (24 時間):